company background image
GRAY

Graybug Vision NasdaqGM:GRAY Stock Report

Last Price

US$0.98

Market Cap

US$20.9m

7D

19.0%

1Y

-79.6%

Updated

02 Jul, 2022

Data

Company Financials +
GRAY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

GRAY Stock Overview

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve.

Graybug Vision Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Graybug Vision
Historical stock prices
Current Share PriceUS$0.98
52 Week HighUS$4.87
52 Week LowUS$0.72
Beta0
1 Month Change-0.41%
3 Month Change-19.01%
1 Year Change-79.63%
3 Year Changen/a
5 Year Changen/a
Change since IPO-94.06%

Recent News & Updates

Jun 29
We're Keeping An Eye On Graybug Vision's (NASDAQ:GRAY) Cash Burn Rate

We're Keeping An Eye On Graybug Vision's (NASDAQ:GRAY) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

GRAYUS PharmaceuticalsUS Market
7D19.0%-0.7%-2.5%
1Y-79.6%10.4%-21.2%

Return vs Industry: GRAY underperformed the US Pharmaceuticals industry which returned 10.4% over the past year.

Return vs Market: GRAY underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is GRAY's price volatile compared to industry and market?
GRAY volatility
GRAY Average Weekly Movement13.8%
Pharmaceuticals Industry Average Movement11.9%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: GRAY is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: GRAY's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201127Fred Guerardhttps://www.graybug.vision

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company’s lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma.

Graybug Vision Fundamentals Summary

How do Graybug Vision's earnings and revenue compare to its market cap?
GRAY fundamental statistics
Market CapUS$20.94m
Earnings (TTM)-US$34.52m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GRAY income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$34.52m
Earnings-US$34.52m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.62
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GRAY perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is GRAY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GRAY?

Other financial metrics that can be useful for relative valuation.

GRAY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does GRAY's PB Ratio compare to its peers?

GRAY PB Ratio vs Peers
The above table shows the PB ratio for GRAY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.9x
VRPX Virpax Pharmaceuticals
0.6x-23.7%US$19.4m
RVPH Reviva Pharmaceuticals Holdings
0.9x8.2%US$18.2m
PTPI Petros Pharmaceuticals
0.5xn/aUS$17.0m
TMBR Timber Pharmaceuticals
1.8xn/aUS$19.4m
GRAY Graybug Vision
0.4x-16.8%US$20.9m

Price-To-Book vs Peers: GRAY is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (0.9x).


Price to Earnings Ratio vs Industry

How does GRAY's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Book vs Industry: GRAY is good value based on its Price-To-Book Ratio (0.4x) compared to the US Pharmaceuticals industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is GRAY's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GRAY PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GRAY's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of GRAY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GRAY's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GRAY's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GRAY's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Graybug Vision forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-16.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GRAY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GRAY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GRAY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GRAY's revenue (43.2% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: GRAY's revenue (43.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GRAY's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Graybug Vision performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


3.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GRAY is currently unprofitable.

Growing Profit Margin: GRAY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GRAY is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.

Accelerating Growth: Unable to compare GRAY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GRAY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).


Return on Equity

High ROE: GRAY has a negative Return on Equity (-61.36%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Graybug Vision's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: GRAY's short term assets ($58.2M) exceed its short term liabilities ($4.2M).

Long Term Liabilities: GRAY's short term assets ($58.2M) exceed its long term liabilities ($102.0K).


Debt to Equity History and Analysis

Debt Level: GRAY is debt free.

Reducing Debt: GRAY has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GRAY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: GRAY has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 0.3% each year.


Discover healthy companies

Dividend

What is Graybug Vision current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GRAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GRAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GRAY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GRAY's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GRAY has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Fred Guerard (49 yo)

3.42yrs

Tenure

US$4,405,460

Compensation

Dr. Frederic Guerard, Pharm D., also known as Fred, has been Director at Lenz Therapeutics, Inc. since 2021. Dr. Guerard has been President, Chief Executive Officer and Director at Graybug Vision, Inc. sin...


CEO Compensation Analysis

Compensation vs Market: Fred's total compensation ($USD4.41M) is above average for companies of similar size in the US market ($USD800.58K).

Compensation vs Earnings: Fred's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: GRAY's management team is considered experienced (2.1 years average tenure).


Board Members

Experienced Board: GRAY's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Graybug Vision, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Graybug Vision, Inc.
  • Ticker: GRAY
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$20.936m
  • Shares outstanding: 21.36m
  • Website: https://www.graybug.vision

Number of Employees


Location

  • Graybug Vision, Inc.
  • 203 Redwood Shores Parkway
  • Suite 620
  • Redwood City
  • California
  • 94065
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/02 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.